Last 41 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 8.60 | — | — | 4.80 | 9.59 | — | — | 18.26 | 7.76 | — | — | — | 33.54 | 20.75 | — | 11.84 | 506.25 | 18.51 | 2721.43 | 5.92 | 39.56 |
| — | — | — | -73.7% | +23.5% | — | — | — | -76.9% | — | — | — | -93.4% | +12.1% | — | +99.9% | +1179.8% | -33.2% | +4082.2% | -52.8% | +682.9% | |
| P/S Ratio | 0.29 | 1.79 | 2.03 | 0.76 | 0.92 | 1.15 | 1.57 | 0.83 | 0.83 | 0.71 | 0.85 | 1.35 | 0.98 | 0.94 | 0.65 | 0.77 | 0.92 | 1.33 | 2.61 | 2.40 | 4.19 |
| — | +55.1% | +29.3% | -8.9% | +10.3% | +61.6% | +84.8% | -38.3% | -14.9% | -24.3% | +31.3% | +76.3% | +6.6% | -29.4% | -75.1% | -68.0% | -78.1% | -70.5% | -56.1% | +12.6% | +305.4% | |
| P/B Ratio | 0.39 | 1.09 | 0.79 | 1.58 | 1.43 | 1.29 | 1.48 | 1.10 | 1.38 | 1.41 | 1.35 | 1.94 | 1.53 | 1.63 | 1.06 | 1.34 | 1.67 | 2.54 | 4.16 | 5.11 | 10.08 |
| — | -15.6% | -46.4% | +43.8% | +4.0% | -8.8% | +10.1% | -43.3% | -10.3% | -13.5% | +27.2% | +45.0% | -8.3% | -36.0% | -74.6% | -73.8% | -83.4% | -79.6% | -73.1% | -20.4% | +58.3% | |
| P/FCF | — | — | 4.21 | 4.92 | 163.56 | — | — | 13.96 | 15.63 | 32.47 | — | 18.50 | 9.86 | 96.29 | — | — | — | 40.17 | — | 24.21 | 42.75 |
| — | — | — | -64.7% | +946.4% | — | — | -24.6% | +58.5% | -66.3% | — | — | — | +139.7% | — | — | — | -3.8% | — | +85.3% | +24.0% | |
| EV / EBITDA | 2.48 | — | — | 2.51 | 4.62 | — | — | 5.64 | 9.31 | — | 835.80 | 12.57 | 8.12 | 9.04 | — | 7.08 | 25.36 | 11.35 | 105.97 | 12.37 | 22.81 |
| — | — | — | -55.5% | -50.4% | — | — | -55.2% | +14.7% | — | — | +77.5% | -68.0% | -20.3% | — | -42.7% | +11.2% | -44.9% | +176.4% | +30.4% | +364.3% | |
| EV / EBIT | 3.67 | — | — | 2.85 | 6.25 | — | — | 8.11 | 15.74 | — | — | — | 13.95 | 12.22 | — | 10.78 | 63.33 | 13.98 | — | 15.29 | 33.35 |
| — | — | — | -64.8% | -60.3% | — | — | — | +12.8% | — | — | — | -78.0% | -12.6% | — | -29.5% | +89.9% | -41.3% | — | +46.5% | +541.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.6% | 45.9% | -2.5% | 77.8% | 75.9% | 72.6% | 72.6% | 75.5% | 76.7% | 77.6% | 73.9% | 72.1% | 76.2% | 77.6% | 75.3% | 76.5% | 77.6% | 78.0% | 74.2% | 74.6% | 77.0% |
| — | -36.8% | -103.4% | +3.1% | -1.1% | -6.4% | -1.7% | +4.6% | +0.7% | +0.0% | -1.8% | -5.7% | -1.8% | -0.6% | +1.5% | +2.5% | +0.8% | +3.1% | -1.3% | -1.9% | -0.3% | |
| Operating Margin | 9.9% | -116.5% | -174.7% | 29.0% | 14.4% | -10.7% | -23.3% | 8.1% | 5.4% | -10.7% | -3.5% | -1.3% | 7.4% | 8.3% | -3.7% | 7.5% | 1.5% | 9.8% | -0.1% | 15.9% | 14.3% |
| — | -984.5% | -650.5% | +259.2% | +165.4% | -0.7% | -564.5% | +733.6% | -26.9% | -228.4% | +5.8% | -116.9% | +387.2% | -15.5% | -2720.2% | -52.6% | -89.4% | -48.7% | -101.1% | -22.0% | -36.8% | |
| Net Margin | 6.6% | -227.0% | -150.9% | 19.4% | 14.3% | -9.3% | -21.7% | 6.1% | 10.7% | -13.1% | -1.9% | -0.6% | 2.9% | 4.5% | -2.8% | 6.5% | 0.2% | 7.2% | -0.9% | 40.2% | 11.1% |
| — | -2336.2% | -594.0% | +220.5% | +33.9% | +28.8% | -1038.3% | +1162.8% | +266.9% | -388.8% | +30.8% | -108.8% | +1485.9% | -37.1% | -193.4% | -83.9% | -98.3% | -57.1% | -109.7% | +132.2% | -46.3% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 9.0% | -29.7% | -13.8% | 10.7% | 5.8% | -2.6% | -5.0% | 2.3% | 4.5% | -6.3% | -0.8% | -0.2% | 1.2% | 2.0% | -1.1% | 2.9% | 0.1% | 3.5% | -0.4% | 24.0% | 6.8% |
| — | -1052.2% | -175.4% | +361.1% | +26.9% | +59.1% | -563.0% | +1230.4% | +293.8% | -416.7% | +32.7% | -107.1% | +1272.3% | -43.4% | -197.7% | -88.1% | -98.8% | -71.4% | -105.7% | +34.6% | -83.3% | |
| ROA | 6.8% | -21.4% | -10.0% | 7.9% | 4.4% | -2.0% | -3.9% | 1.6% | 2.8% | -3.8% | -0.5% | -0.1% | 0.7% | 1.2% | -0.7% | 1.7% | 0.0% | 2.0% | -0.2% | 12.7% | 3.5% |
| — | -960.1% | -157.2% | +385.1% | +60.2% | +46.5% | -753.8% | +1420.3% | +299.6% | -418.7% | +31.0% | -107.5% | +1373.0% | -39.5% | -219.4% | -87.0% | -98.6% | -68.0% | -106.4% | +84.4% | -61.4% | |
| ROIC | 10.9% | -11.4% | -11.7% | 11.7% | 4.7% | -2.6% | -5.1% | 2.6% | 1.6% | -3.5% | -1.0% | -0.3% | 2.0% | 2.4% | -1.0% | 2.3% | 0.5% | 3.3% | -0.0% | 6.7% | 6.1% |
| — | -343.1% | -129.7% | +346.9% | +190.1% | +26.4% | -430.9% | +922.3% | -18.1% | -245.4% | +6.2% | -113.8% | +310.1% | -27.4% | -2696.7% | -65.5% | -92.1% | -64.3% | -100.6% | -41.5% | -54.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.31 | 0.23 | 0.19 | 0.31 | 0.11 | 0.11 | 0.12 | 0.11 | 0.39 | 0.43 | 0.43 | 0.43 | 0.45 | 0.46 | 0.47 | 0.47 | 0.51 | 0.52 | 0.54 | 0.55 | 0.59 |
| — | +105.6% | +60.4% | +172.4% | -72.6% | -73.6% | -72.9% | -73.8% | -14.4% | -6.9% | -9.5% | -8.1% | -11.5% | -11.1% | -11.9% | -15.0% | -13.9% | -17.5% | -15.1% | -8.3% | -66.2% | |
| Debt / EBITDA | 1.60 | — | — | 1.84 | 1.43 | — | — | 2.95 | 10.11 | — | 980.73 | 10.83 | 9.00 | 9.45 | — | 9.33 | 29.34 | 8.96 | 53.36 | 5.23 | 5.34 |
| — | — | — | -37.7% | -85.9% | — | — | -72.7% | +12.4% | — | — | +16.1% | -69.3% | +5.4% | — | +78.2% | +449.6% | +118.3% | +760.8% | +48.0% | +17.2% | |
| Current Ratio | 3.62 | 3.52 | 3.53 | 3.62 | 3.32 | 3.95 | 4.12 | 3.69 | 3.09 | 2.73 | 2.74 | 2.80 | 2.77 | 2.95 | 2.85 | 2.97 | 2.58 | 2.62 | 2.84 | 2.74 | 2.62 |
| — | -11.0% | -14.3% | -2.0% | +7.5% | +44.7% | +50.2% | +32.0% | +11.5% | -7.3% | -3.7% | -5.8% | +7.2% | +12.3% | +0.5% | +8.1% | -1.3% | +10.0% | +13.3% | +7.4% | +34.3% | |
| Quick Ratio | 3.32 | 3.00 | 3.16 | 3.32 | 2.88 | 3.45 | 3.67 | 3.35 | 2.74 | 2.42 | 2.41 | 2.44 | 2.43 | 2.60 | 2.51 | 2.64 | 2.31 | 2.36 | 2.54 | 2.44 | 2.25 |
| — | -13.0% | -14.0% | -0.9% | +5.3% | +42.7% | +52.4% | +37.1% | +12.8% | -7.0% | -4.2% | -7.3% | +5.2% | +10.2% | -1.0% | +8.0% | +2.4% | +14.9% | +20.9% | +13.7% | +50.4% | |
| Interest Coverage | — | — | — | — | — | — | — | 167.08 | 13.36 | -22.45 | -7.45 | -2.58 | 18.20 | 16.45 | -6.13 | — | 3.12 | 16.32 | -0.18 | 23.96 | 9.69 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 41 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORGO stock.
Organogenesis Holdings Inc.'s current P/E is 8.6x. The average P/E over the last 2 quarters is 7.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Organogenesis Holdings Inc.'s current operating margin is 9.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Organogenesis Holdings Inc.'s business trajectory between earnings reports.